About investor relations

Henry Schein at a Glance

About investor relations

$12.6B IN SALES IN 2022


Our Q1 Results Reflect

  • Strong internal sales growth of 6.3% in local currencies (excluding PPE products and COVID-19 Test Kits), reflecting the underlying health of our business.
  • Updated 2023 non-GAAP diluted EPS guidance to $5.18 - $5.35, to include effects of the Biotech Dental acquisition.
  • Strong operating performance advancing our BOLD+1 Strategy.

At Henry Schein, Inc., our customers rely on us for an exceptional experience

Delivering differentiated solutions that make their practices more successful and improve patient outcomes. We are trusted advisors and consultants to our customers – enabling them to deliver the best quality patient care and enhance their practice management efficiency and profitability.

With more than 3,400 field sales consultants (including equipment sales specialists), approximately 2,100 telesales representatives, and more than 170 equipment sales and service centers worldwide, Henry Schein helps customers succeed by offering the products and services needed for delivering high-quality health care.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.